Marketing FDA calls meeting to weigh quick cancer approvals, threatening Merck, BMS and Roche
Another day, another article on FDA getting really serious on those non-performing drugs on certain indications. The FDA wants them removed. But the likes of Merck, BMS and Roche wants to keep the revenue coming. Ultimately, FDA has the power to remove them which means the big pharma will have to look for a new dance partner that works to continue their revenue and market share. It is really heating up now. Great timing for release of the beautiful data of Her-Vaxx in the upcoming AACR
Marketing FDA calls meeting to weigh quick cancer approvals,...
-
- There are more pages in this discussion • 13,964 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |